Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
11/30/2020 12/01/2020 12/02/2020 12/03/2020 12/04/2020 Date
1370(c) 1381(c) 1393.6(c) 1374.8(c) 1386(c) Last
12 699 409 8 556 615 7 880 363 8 555 664 7 418 660 Volume
-0.98% +0.80% +0.91% -1.35% +0.81% Change
More quotes
Financials
Sales 2020 34 273 M 46 053 M 46 053 M
Net income 2020 4 851 M 6 519 M 6 519 M
Net Debt 2020 22 923 M 30 802 M 30 802 M
P/E ratio 2020 14,1x
Yield 2020 5,77%
Sales 2021 35 407 M 47 577 M 47 577 M
Net income 2021 4 226 M 5 678 M 5 678 M
Net Debt 2021 21 265 M 28 574 M 28 574 M
P/E ratio 2021 16,4x
Yield 2021 5,77%
Capitalization 68 991 M 92 941 M 92 704 M
EV / Sales 2020 2,68x
EV / Sales 2021 2,55x
Nbr of Employees 99 437
Free-Float 92,3%
More Financials
Company
GlaxoSmithkline plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (52%): intended for respiratory diseases (67.5% of net sales), HIV infection (27.7%), immune system disorders (3.5%) ) and cancer (1,3%); - OTC and parapharmaceutical medicine (26.7%); - vaccines (21.2%); - other (0.1%). Net sales are distributed geographically as... 
Sector
Pharmaceuticals
Calendar
12/05Presentation
More about the company
Notations Surperformance© of GlaxoSmithKline plc
Trading Rating : Investor Rating :
More Ratings
All news about GLAXOSMITHKLINE PLC
12/03VOLUNTARY AND FREE : Portugal approves COVID-19 vaccination plan
RE
12/03Sanofi to publish COVID-19 vaccine price in development with GSK after Phase ..
RE
12/03GLAXOSMITHKLINE : Downgraded to Neutral by UBS
MD
12/03Merck KGaA agrees research deal with Artios for 'DNA damage' cancer drugs
RE
12/03Merck KGaA agrees research deal with Artios for 'DNA damage' cancer drugs
RE
12/01U.S. plans for first COVID vaccines as pandemic deaths surge again
RE
12/01ViiV Healthcare and Shutterstock Studios unite to tackle outdated perceptions..
AQ
12/01GLAXOSMITHKLINE : ViiV Healthcare and the Medicines Patent Pool expand access to..
AQ
11/26French health minister confirms vaccination could start by end of year
RE
11/25How will Canada's COVID-19 vaccine program work?
RE
11/25EXPLAINER : When and how will COVID-19 vaccines become available?
RE
11/24AstraZeneca Gears Up to Vaccinate the World Against Covid-19
DJ
11/23GLAXOSMITHKLINE : GSK starts phase 3 study of RSV maternal candidate vaccine
AQ
11/23GLAXOSMITHKLINE : GSK starts phase 3 study of RSV maternal candidate vaccine
PU
11/21FDA Authorizes Regeneron's Covid-19 Antibody Cocktail Drug -- Update
DJ
More news
News in other languages on GLAXOSMITHKLINE PLC
12/03GSK : en repli, un analyste abaisse son conseil
12/03GLAXOSMITHKLINE : UBS n'est plus acheteur
12/03UBS senkt GlaxoSmithKline auf 'Neutral' - Ziel 1440 Pence
12/03GLAXOSMITHKLINE : en repli, un analyste abaisse son conseil
12/03GSK : UBS n'est plus à 'achat'
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | MarketScreener
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 1 696,48 GBX
Last Close Price 1 386,00 GBX
Spread / Highest target 69,6%
Spread / Average Target 22,4%
Spread / Lowest Target -20,2%
EPS Revisions
Managers
NameTitle
Emma N. Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC-22.09%92 316
JOHNSON & JOHNSON3.02%392 249
ROCHE HOLDING AG-4.55%287 762
PFIZER, INC.8.67%222 836
NOVARTIS AG-11.95%206 585
MERCK & CO., INC.-10.45%206 071